Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2018 Oct 18

PMID 30328521

Citations 71

Authors

Petter Bjornstad

Robert H Eckel

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Insulin resistance (IR) is recognized to play an important role in the pathogenesis of dyslipidemia. This review summarizes the complex interplay between IR and dyslipidemia in people with and without diabetes.

Recent Findings: IR impacts the metabolism of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) by several mechanisms. Trials with insulin sensitizing therapies, including biguanides and thiazolidinediones, have provided inconsistent results on lipid lowering in people with and without diabetes. In this review, we focus on the pathophysiological interplay between IR and dyslipidemia and recapitulate lipid and lipoprotein data from insulin-sensitizing trials. Further research elucidating the reciprocal relationship between IR and dyslipidemia is needed to better target these important risk factors for cardiovascular disease.

Citing Articles

Non-linear association of the metabolic score for insulin resistance with obstructive sleep apnea: a cross-sectional study from NHANES 2015-2018.

Cai Z, Li J, Peng H, Ye Y, Chen S, Zeng L Front Nutr. 2025; 12:1545140.

PMID: 40078414 PMC: 11899179. DOI: 10.3389/fnut.2025.1545140.

Association of metabolic score for insulin resistance with incident metabolic syndrome: a cohort study in middle-aged and older adult Chinese population.

Zhang Q, Wei Y, Huang S, Mo Y, Yan B, Jin X Front Public Health. 2025; 13:1453144.

PMID: 40051521 PMC: 11883690. DOI: 10.3389/fpubh.2025.1453144.

Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders.

Cheng M, Ding F, Li L, Dai C, Sun X, Xu J Front Pharmacol. 2025; 16:1517174.

PMID: 39950117 PMC: 11822302. DOI: 10.3389/fphar.2025.1517174.

Is Insulin Resistance an Independent Predictor of Atherosclerosis?.

Landowska M, Kaluza B, Watala C, Babula E, Zuk-Lapan A, Wozniak K J Clin Med. 2025; 14(3).

PMID: 39941639 PMC: 11818120. DOI: 10.3390/jcm14030969.

Association between the atherogenic index of plasma and long-term risk of type 2 diabetes: a 12-year cohort study based on the Japanese population.

Zhou Q, Wu Y, Li M Cardiovasc Diabetol. 2025; 24(1):50.

PMID: 39885511 PMC: 11783948. DOI: 10.1186/s12933-025-02605-y.

References

Yost T, Froyd K, JENSEN D, Eckel R . Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism. 1995; 44(6):786-90. DOI: 10.1016/0026-0495(95)90193-0. View

Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View

Labadzhyan A, Cui J, Peterfy M, Guo X, Chen Y, Hsueh W . Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans. PLoS One. 2016; 11(11):e0166263. PMC: 5112869. DOI: 10.1371/journal.pone.0166263. View

Medina-Santillan R, Lopez-Velazquez J, Chavez-Tapia N, Torres-Villalobos G, Uribe M, Mendez-Sanchez N . Hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev. 2013; . DOI: 10.1002/dmrr.2410. View

Mautner S, Lin F, Roberts W . Composition of atherosclerotic plaques in the epicardial coronary arteries in juvenile (type I) diabetes mellitus. Am J Cardiol. 1992; 70(15):1264-8. DOI: 10.1016/0002-9149(92)90759-r. View

Madsen A, Bozickovic O, Bjune J, Mellgren G, Sagen J . Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2). Sci Rep. 2015; 5:16430. PMC: 4637908. DOI: 10.1038/srep16430. View

Eckel R, Yost T, JENSEN D . Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord. 1995; 19 Suppl 1:S16-21. View

Garg A, Haffner S . Insulin resistance and atherosclerosis. Diabetes Care. 1996; 19(3):274. DOI: 10.2337/diacare.19.3.274. View

Xiao C, Dash S, Morgantini C, Adeli K, Lewis G . Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism. Diabetes. 2015; 64(7):2310-8. DOI: 10.2337/db14-1706. View

10.

Qiao L, Zou C, van der Westhuyzen D, Shao J . Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008; 57(7):1824-33. PMC: 2453618. DOI: 10.2337/db07-0435. View

11.

Boden G, Jadali F, White J, Liang Y, Mozzoli M, Chen X . Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest. 1991; 88(3):960-6. PMC: 295496. DOI: 10.1172/JCI115399. View

12.

Goodarzi M, Guo X, Taylor K, Quinones M, Saad M, Yang H . Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Diabetes. 2003; 53(1):214-20. DOI: 10.2337/diabetes.53.1.214. View

13.

Xu T, Brandmaier S, Messias A, Herder C, Draisma H, Demirkan A . Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015; 38(10):1858-67. DOI: 10.2337/dc15-0658. View

14.

Brinton E, Eisenberg S, Breslow J . Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat.... Arterioscler Thromb. 1994; 14(5):707-20. DOI: 10.1161/01.atv.14.5.707. View

15.

Wadwa R, Kinney G, Maahs D, Snell-Bergeon J, Hokanson J, Garg S . Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care. 2005; 28(5):1051-6. DOI: 10.2337/diacare.28.5.1051. View

16.

Nadeau K, Chow K, Alam S, Lindquist K, Campbell S, McFann K . Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2014; 16(3):196-203. PMC: 4185016. DOI: 10.1111/pedi.12140. View

17.

Chapman M, Ginsberg H, Amarenco P, Andreotti F, Boren J, Catapano A . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-61. PMC: 3105250. DOI: 10.1093/eurheartj/ehr112. View

18.

Ng T, Watts G, Farvid M, Chan D, Barrett P . Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes. 2005; 54(3):795-802. DOI: 10.2337/diabetes.54.3.795. View

19.

Libby P, Nathan D, Abraham K, Brunzell J, Fradkin J, Haffner S . Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005; 111(25):3489-93. DOI: 10.1161/CIRCULATIONAHA.104.529651. View

20.

Kollerits B, Auinger M, Reisig V, Kastenbauer T, Lingenhel A, Irsigler K . Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care. 2006; 29(7):1661-3. DOI: 10.2337/dc06-0546. View